key: cord-1038594-08canirh
authors: Naranbhai, Vivek; Nathan, Anusha; Kaseke, Clarety; Berrios, Cristhian; Khatri, Ashok; Choi, Shawn; Getz, Matthew A.; Tano-Menka, Rhoda; Ofoman, Onosereme; Gayton, Alton; Senjobe, Fernando; Zhao, Zezhou; St Denis, Kerri J.; Lam, Evan C.; Carrington, Mary; Garcia-Beltran, Wilfredo F.; Balazs, Alejandro B.; Walker, Bruce D.; Iafrate, A. John; Gaiha, Gaurav D.
title: T-cell reactivity to the SARS-CoV-2 Omicron variant is preserved in most but not all individuals
date: 2022-02-03
journal: Cell
DOI: 10.1016/j.cell.2022.01.029
sha: 68101272e5fbc72c035969d2a67f00362c254a4f
doc_id: 1038594
cord_uid: 08canirh

The SARS-CoV-2 Omicron variant (B.1.1.529) contains mutations that mediate escape from antibody responses, although the extent to which these substitutions in spike and non-spike proteins affect T-cell recognition is unknown. Here we show that T-cell responses in individuals with prior infection, vaccination, both prior infection and vaccination, and boosted vaccination are largely preserved to Omicron spike and non-spike proteins. However, we also identify a subset of individuals (∼21%) with a >50% reduction in T-cell reactivity to the Omicron spike. Evaluation of functional CD4+ and CD8+ memory T cell responses confirmed these findings and reveal that reduced recognition to Omicron spike is primarily observed within the CD8+ T cell compartment potentially due to escape from HLA binding. Booster vaccination enhanced T-cell responses to Omicron spike. In contrast to neutralizing immunity, these findings suggest preservation of T-cell responses to the Omicron variant, although with reduced reactivity in some individuals.

The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) Omicron variant (B.1.1.529), first identified in November 2021, has been the cause of a new surge of infections globally (Viana et al., 2021) . With as many as 36 substitutions in the viral spike protein and 59 mutations in total throughout its genome, Omicron has been found to evade neutralization by infection-and vaccine-induced antibodies with unprecedented frequency (Garcia-Beltran et al., 2021a; Hoffmann et al., 2021) and escape neutralization by most therapeutic monoclonal antibodies (Ikemura et al., 2021; VanBlargan et al., 2021) .

Additional booster vaccine doses partially compensate for this effect (Garcia-Beltran et al., 2021b; Hoffmann et al., 2021) , but the durability of such protective antibody response remains to be determined. Thus, whether additional arms of the adaptive immune response,

namely T-cell responses, can augment protection against Omicron infection and disease is of considerable interest and has implications for predicting the course of future SARS-CoV-2 variants.

In individuals with previous SARS-CoV-2 infection and vaccinees, robust T-cell responses are quantitatively and qualitatively associated with milder outcomes (Rydyznski . Early induction of antigen-specific CD4 + T cells following vaccination is associated with coordinated generation of antibody and CD8 + T-cell responses (Painter et al., 2021) . Previous studies have also shown a key role for CD8 + T cells in mitigating COVID-19 disease severity and inducing long-term immune protection.

Mild COVID-19 disease is associated with increased clonal expansion of CD8 + T cells in bronchoalveloar lavage fluid (Liao et al., 2020) , robust CD8 + T-cell reactivity to SARS-CoV-2 epitopes (Peng et al., 2020; Sekine et al., 2020) , and rapid CD8 + T-cell-mediated viral clearance (Tan et al., 2021) . In addition, depletion of CD8 + T cells from convalescent macaques reduced protective immunity (McMahan et al., 2020) . Given that T cells can target regions across the SARS-CoV-2 proteome and are not limited solely to the spike protein, it is perhaps not unexpected that prior SARS-CoV-2 variants were able to escape neutralizing antibody responses (Garcia-Beltran et al., 2021a) but not T cells (Geers et al., 2021) . Thus, in light of the emergence of the Omicron variant, we sought to determine the extent to which mutations in the variant spike and non-spike proteins affect CD4 + and CD8 + T-cell reactivity.

Utilizing samples from prior SARS-CoV-2 infected, vaccinated, and both prior infected and vaccinated individuals, we found that circulating effector T-cell responses and both CD4 + and CD8 + memory T-cell responses were generally preserved to the Omicron variant.

However, distinct from previous variants of concern (VOC), such as Delta, a subset of individuals had reduced effector and memory T-cell recognition to the Omicron spike protein relative to wildtype spike, with a particularly noticeable effect on spike-specific CD8 + T-cell memory responses. Booster doses enhanced the magnitude of responses to wildtype and Omicron spike, although did not completely mitigate the comparatively reduced T-cell reactivity to Omicron in individual participants. These findings therefore have important implications in ascertaining the role of immune responses in morbidity and mortality due to Omicron and may inform the development of variant-specific and variant-resistant secondgeneration vaccines.

J o u r n a l P r e -p r o o f

sampled prior to vaccination, after primary series vaccination, and/or after receipt of additional 'booster' doses. Study groups were stratified by prior infection (confirmed by antinucleocapsid antibody testing) and vaccination status (Table S1 ). In total, we studied 101 samples from 76 donors ( Figure 1A ). The median age was 45 years (range 37-60 years) and 64% were female. Of the previously infected individuals, we included 11 unvaccinated, 12 vaccinated sampled after initial vaccination series, and 13 vaccinated and sampled after booster doses. Among individuals without previous infection, we included 10 unvaccinated, 24 sampled after initial vaccination series, and 31 vaccinated and sampled after booster doses. Samples were obtained at a median 220 (range 130-286) days after primary series vaccination or 10 days (range 8-54) after additional booster doses. The primary analysis of host, vaccine, and variant variables that affect T-cell responses was by multivariate regression.

To assess the total (CD4 + and CD8 + ) effector T-cell response, we performed an IFN- ELISpot following stimulation with pooled overlapping 15mer peptides spanning the full length of the wildtype, Delta (B.1.617.2), or Omicron (B.1.1.529) spike protein and the nonspike SARS-CoV-2 structural and accessory proteins (nucleocapsid, membrane, enveloped and open reading frame 3A, i.e. NC/M/E/3A) from wildtype and Omicron. The evaluated peptides span the full-length of spike: relative to wildtype, 27.3% (86/315) spike peptides were unique to Omicron and 8.6% (27/315) to Delta. For the NC/M/E/3A pools, the evaluated peptides span the full-length of the respective proteins: relative to wildtype, 10.1% (24/237) of the peptides were unique to Omicron (Table S2 ). In the primary multivariate analysis of T-cell reactivity (Table S3) , the magnitude of effector T-cell responses to spike and nonspike proteins did not vary by variant, and was not affected by age, sex and primary vaccine series. However, examination of individual responses reveals specific patients in whom responses to the Omicron spike were reduced by >50% ( Figure 1B , denoted in red). Prior J o u r n a l P r e -p r o o f infection, duration after primary series vaccination, and receipt of an additional 'booster' dose were independently associated with magnitude of response (Table S3 ).

The background response to wildtype, Delta or Omicron peptide pools in individuals without prior SARS-CoV-2 infection or vaccination had median values of 0-5 SFU/10 6 PBMCs ( Figure S1 ). The median effector T-cell reactivity against wildtype and Omicron spike (in SFU/10 6 PBMC) was 152 and 114 for individuals with prior infection; 43 and 42 for individuals after primary series vaccination (without prior infection); and 311 and 315 for individuals with prior infection after primary series vaccination ( Figure 1C ). In comparison, the median effector T-cell reactivity against delta spike (in SFU/10 6 PBMC) was 155 for individuals with prior infection; 34 for individuals after primary series vaccination (without prior infection); and 277 for individuals with prior infection after primary series vaccination ( Figure 1D ). Regardless of variant, prior infection was associated with a higher magnitude of effector T-cell responses (0.55 log10 SFU/10 6 PBMC higher response, 95%CI 0.38-0.72, p<0.001). Effector T-cell responses declined modestly over time (-0.02 log10 SFU/10 6 PBMC lower response per week, 95%CI -0.05,0.00, p=0.028). Neither age nor sex influenced responses, and in this analysis primary vaccine type was not associated with differences in responses (Table S3) . Surprisingly, 21.2% (10/47) of participants with prior infection and/or vaccination had a >50% (0.3log10) reduction in T-cell response to Omicron spike (denoted in red in Figure 1C ), with 12.7% of participants (6/47) having a >70% (0.5 log10) reduction.

In contrast, only 9.7% (4/41) of participants with prior infection and/or vaccination had a >50% (0.3log10) reduction in overall effector T-cell response to Delta spike. Thus, while Tcell responses induced by prior infection and/or vaccination are broadly cross-reactive at a population level, a distinct subset of individuals have substantially reduced T-cell recognition of the mutated Omicron spike protein.

In contrast to spike-specific T-cell responses, T-cell reactivity against wildtype and Omicron NC/M/E/3A was preserved in all individuals with prior infection (with or without subsequent vaccination). The median effector T-cell reactivity against wildtype and Omicron NC/M/E/3A (in SFU/10 6 PBMC) was 275 and 220 for individuals with prior infection; 1 and 0 for individuals after primary series vaccination (without prior infection); and 160 and 237 for J o u r n a l P r e -p r o o f individuals with prior infection and after primary series vaccination ( Figure 1E ). In individuals with prior infection or prior infection and vaccination, the magnitude of reactivity towards NC/M/E/3A was correlated with that of spike for wildtype and Omicron peptides ( Figure S2 ).

Individuals with prior infection demonstrated higher T-cell responses to spike, suggesting that repeated exposure to antigen may potentially enhance cross-reactive T-cell responses.

We therefore assessed the impact of booster vaccination on T-cell reactivity by IFN- ELISpot. Similar to the evaluation of pre-boost samples, overall effector T-cell responses towards wildtype and Omicron spike across our study participants were comparable postbooster ( Figure 2B ). Moreover, receipt of a booster dose was associated with a 1.1log10 SFU/10 6 PBMC increase (95% CI 0.91-1.2, p<0.001) in the magnitude of T-cell response (Table S3) , with specific fold increases of 20.1 against wildtype and 20.4 against Omicron in 25 participants with paired sampling ( Figure 2C ). However, even after booster vaccination, 9.1% (4/44) participants still demonstrated >50% reduced reactivity to Omicron spike relative to wildtype. Overall, the frequency of >50% reduced effector T-cell responses to the Omicron variant was more frequent than to Delta in 85 individual sample points with both measures (Fisher's exact p-value 0.023, Table S4 ).

To assess the cross-reactivity of functional CD4 + and CD8 + memory T-cell responses to Omicron, we performed a 6-day carboxyfluorescein succinimidyl ester (CFSE) proliferation assay ( Figure S3 ) on samples from individuals who were vaccinated and/or previously infected and/or received booster vaccine doses (n = 33 participants) using overlapping wildtype or Omicron spike peptide pools. We felt it was important to utilize this assay given that antigen-specific proliferation has been strongly associated with functional T-cell responses and cytotoxicity (Migueles et al., 2002 (Migueles et al., , 2008 Ndhlovu et al., 2013) . The patient cohort studied here was a subset of that used for the IFN- ELISpot assay, wherein 11 samples were from vaccinated individuals, 13 from previously infected and vaccinated J o u r n a l P r e -p r o o f individuals, and nine from vaccinated and boosted individuals (five of whom were also previously infected). A paired t-test demonstrated that while the magnitude of proliferative spike-specific CD4 + T-cell responses did not vary by variant, proliferative CD8+ T-cell responses to Omicron spike were decreased compared to wildtype in previously infected, vaccinated participants (p = 0.009) and across all study participants (p < 0.005), which is further illustrated by examination of individual patient responses ( Figure 3A , denoted in red).

CD4 + proliferative responses remained largely cross-reactive to Omicron spike, with only 12% (4/33) of individuals with prior infection and/or vaccination and/or booster showing a >50% (0.3log10) reduction ( Figure 3B) . A larger proportion of 39% of individuals (13/33) exhibited a decreased CD8 + T-cell proliferative response to Omicron spike ( Figure 3C ). A multivariate regression analysis revealed that neither age nor sex influenced CD4 + or CD8 + T-cell responses, but proliferative CD8 + responses tended to be lower for Omicron vs wildtype after adjusting for all covariates and were significantly increased by booster doses (Table S5 ). These data indicate that the reduced reactivity in a subset of individuals to the Omicron spike protein is primarily observed in the CD8 + T-cell compartment, although this can be enhanced with booster vaccination.

To determine whether mutations in the Omicron spike protein could affect recognition of HLA class I-restricted CD8+ T cell epitopes, we computationally assessed the predicted binding affinity of all 8-11mer peptides in the wildtype (N = 5058) and Omicron spike (N = 5050) for 150 HLA-A, -B, and -C alleles using NetMHCpan4.1 (Reynisson et al., 2020) . We chose to evaluate this large group of HLA alleles in order to be as comprehensive as possible given the global nature of the pandemic. This identified 736 unique epitopes that were predicted to be strong binders to HLA class I molecules (Table S6 ). The majority of these epitopes (83.2%, 612/736) were identical in sequence between wildtype and Omicron, and of the 16.8% (124/736) epitopes that had sequence differences, 60.4% (75/124) retained similar predicted HLA class I binding affinity. However, for the remaining epitopes with sequence differences (6.7%, 49/736), the Omicron spike mutations resulted in a predicted loss of binding to one or more HLA alleles (Table 1) . Thus, the analysis provides J o u r n a l P r e -p r o o f a possible explanation as to why the mutations in the Omicron spike protein could lead to a decrease in epitope presentation and subsequently T-cell reactivity.

In addition, we obtained the HLA haplotypes for 10 individuals with a >50% reduction in either their effector or memory T-cell responses to the Omicron spike. Interestingly, all of these study participants expressed at least three HLA class I alleles that are well bound by wildtype-derived epitopes, but which are predicted to be non-binders to corresponding Omicron-derived epitopes (Table S7) . Indeed, the majority (60%, 6/10 individuals) carried between 4-6 HLA class I alleles affected by Omicron spike mutations (Table 1) , illustrating a putative susceptibility to viral epitope escape.

Within this cohort of individuals, we recently reported markedly reduced neutralization of Omicron following primary series vaccination, which was overcome by additional 'booster' (Greaney et al., 2021) . In contrast, we found that Tcell reactivity was relatively preserved in most individuals against Omicron, and in many individuals with undetectable omicron neutralizing antibody responses, effector T-cell responses were measurable. Conservation of sequence identity and comparable predicted HLA class I binding affinity of most putative CD8 + T cell epitopes between the wildtype and Omicron spike across a set of alleles with global coverage likely explains the preservation of spike-specific T-cell responses observed in 80% of individuals in the study. Previous studies have identified an association between T-cell immunity and mild COVID-19 disease (Peng et al., 2020; Rydyznski Moderbacher et al., 2020; Tan et al., 2021) . In addition, in animal models of SARS-CoV- 2 (McMahan et al., 2020) , T-cell responses appear to be important in reducing disease acquisition and severity. Thus, the high frequency of preserved T-cell responses against Omicron suggests that T-cell responses may be responsible for vaccine effectiveness (and also from natural infection) against severe J o u r n a l P r e -p r o o f outcomes from Omicron infection that appear higher than predicted by absent or lower neutralization.

For the subset of individuals with reduced T-cell reactivity, these findings were somewhat unexpected given that the vast majority of the spike protein in Omicron is sequence conserved in comparison to wildtype (97.2%, i.e. 1237/1273 amino acids unchanged).

However, computational HLA-peptide binding affinity assessments suggest that at least a subset of predicted unique epitopes in the Omicron spike protein may lose their ability to bind to HLA molecules. Therefore, it is possible that Omicron spike variation affects key residues critical to HLA binding that mediate escape from specific HLA-restricted T-cell responses induced by prior infection and vaccination. Because HLA binding prediction algorithms are not fully reliable in their identification of immunogenic epitopes, additional experimental data by specific epitope mapping will be important to obtain. The observation that 10 study participants with reduced effector or memory T-cell responses expressed between 3-6 HLA class I alleles that are putatively affected by Omicron spike mutations due to a loss in epitope binding provides additional support for this potential mechanism. Further analyses of larger cohorts of individuals could augment these findings and assist in the identification of specific HLA class I alleles that provide a disproportionate susceptibility to viral epitope escape.

Prior SARS-CoV-2 infection, despite being remote, was associated with higher T cell effector and memory responses than vaccination alone, and responses were directed against both spike and non-spike proteins in contrast to being focused solely on spike. This may reflect the impact of distinct antigen kinetics and multiple antigen exposures during infection leading to qualitatively different responses in comparison to vaccination. The preservation of T-cell reactivity to non-spike structural and accessory proteins in all individuals is likely due to the substantially reduced number of mutations within NC/M/E/3A relative to spike, suggesting that these proteins may be highly attractive for second-generation COVID-19 vaccines. In particular, vaccine strategies that induce robust memory and effector T cell responses alongside antibody responses which are collectively targeted against conserved, variant-J o u r n a l P r e -p r o o f resistant sites (Meyers et al., 2021; Nathan et al., 2021) may yield more durable T cell immunity capable of providing broad protection against future variants.

Collectively, these data provide insight into the immune mechanisms that may account for clinical observation of Omicron pathophysiology and demonstrate the contribution of vaccine boosters to enhancing cellular immunity to SARS-CoV-2 variants. They also raise the prospect that future SARS-CoV-2 variants may variably escape from antibody or T-cell responses. These findings thereby support continued evaluation of second-generation vaccine approaches that induce robust T-cell responses that target both variant spike and non-spike antigens in order to overcome current and future SARS-CoV-2 evolution.

Our study has some noteworthy limitations. First, this is a study of dynamic immune responses with distinct kinetics but timing of sampling was constrained to ~6 months after primary series vaccination and sooner after booster doses. Secondly, although we included individuals with prior infection, primary series vaccination and booster vaccines with the three vaccines deployed in the USA (mRNA1273, BNT162b2 and Ad26.COV2.S), each group is relatively small and cannot comprehensively capture the variables that may plausibly affect reactivity such as the variant with which individuals were infected, the wide variety of vaccines deployed globally, differences in the timing of booster doses, and time of sampling after booster vaccination. Thirdly, we employed IFN- ELISPOT and proliferation assays to estimate T-cell responses. While these assays are sensitive for functionally relevant T-cell responses (Goonetilleke et al., 2006; Karlsson et al., 2003) , further interrogation of the phenotype and function of responding cells could also be pursued.

Moreover, additional assays to assess T-cell reactivity to Omicron spike, such as the activation induced marker assay , intracellular cytokine staining following peptide stimulation or multimer staining (Saini et al., 2021) , could be employed to detect SARS-CoV-2 specific T cell responses, although a quantitative threshold of protection for any of these assays has not been clearly established. 

G.D.G has filed patent application PCT/US2021/028245.

We worked to ensure gender balance in the recruitment of human subjects. We worked to ensure ethnic or other types of diversity in the recruitment of human subjects. We worked to ensure that the study questionnaires were prepared in an inclusive way. One or more of the authors of this paper self-identifies as an underrepresented ethnic minority in science. One or more of the authors of this paper self-identifies as a member of the LGBTQ+ community.

Schematic of the study created with Biorender.com: Participants were enrolled in Chelsea, Massachusetts and stratified according to whether they had documented asymptomatic or symptomatic SARS-CoV-2 infection (ascertained by anti-nucleocapsid antibody testing) and vaccination status (see Table S1 ). 101 PBMC samples from 76 individuals were studied. 25 individuals provided samples prior to and after receipt of additional booster vaccine doses.

Total (CD4 + and CD8 + ) effector T-cell reactivity to SARS-CoV-2 overlapping peptide pools from wildtype, Omicron or Delta spike and from wildtype or Omicron non-spike structural and accessory proteins (nucleocapsid/membrane/envelope/ORF3A, i.e. NC/M/E/3A) was assessed by IFN- ELISpot (the number is shown for each group). CD4 + and CD8 + memory T-cell response to wildtype or Omicron spike was assessed in a subset of participants by CFSE-based proliferation assay (see Figure 3 ). Numbers for each group are shown in J o u r n a l P r e -p r o o f parentheses. Table S2 describes Figure S1 , Figure S2 , Table S1, Table S2, Table S3 and Table S4 . Table S3 and Table S4 . individuals (p = 0.009) and across all study participants (p < 0.005) to wildtype vs. Omicron spike by a paired t-test (not adjusted for multiple comparisons or covariates) revealed a significant reduction in response to Omicron spike. See Figure S3 and Table S5 . (Reynisson et al., 2020) were used to define strong binders as those with an EL_Rank score <0.5, weak binders as those with scores >0.5 and <2.0 and non-binders as those with scores >2.0.

See also Table S6 and Table S7 J o u r n a l P r e -p r o o f 

Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Gaurav D. Gaiha (ggaiha@mgh.harvard.edu).

The overlapping pools of 15mer peptides from the Omicron spike, nucleocapsid, membrane and envelope proteins generated in this study will be made available on request after completion of a Materials Transfer Agreement. Antibodies and other reagents are available from their respective sources.

  This paper does not report original code.

 Any additional information required to reanalyze the data reported in this work is available from the Lead Contact upon request.

Use 

Complete overlapping 15mer Spike, Nucleocapsid, Membrane, and Envelope peptides (15mer peptide overlapping by 11 amino acids) from the SARS-CoV-2 Omicron (B.1.1.529) variant were synthesized on automated robotic peptide synthesizers (AAPPTEC, 396

Models MBS, Omega and Apex) by using Fmoc solid-phase chemistry (Behrendt et al., 2016) on 2-chlorotrityl chloride resin (Chatzi et al., 1991) . The C-terminal amino acids were loaded using the respective Fmoc-Amino Acids in the presence of DIEA. Unreacted sites on the resin were blocked using methanol, DIEA and DCM (15:5:80 v/v). Subsequent amino acids were coupled using optimized (to generate peptides containing more than 90% of the desired full-length peptides) cycles consisting of Fmoc removal (deprotection) with 25% Piperidine in NMP followed by coupling of Fmoc-AAs using HCTU/NMM activation. Each deprotection or coupling was followed by several washes of the resin with DMF to remove excess reagents. After the peptides were assembled and the final Fmoc group removed, J o u r n a l P r e -p r o o f peptide resin was then washed with dimethylformamide, dichloromethane, and methanol three times each and air dried. Peptides were cleaved from the solid support and deprotected using odor free cocktail (TFA/triisopropyl silane/water/DODT; 94/2.5/2.5/1.0 v/v) for 2.5h at room temperature (Teixeira et al., 2002) . Peptides were precipitated using cold methyl tertiary butyl ether (MTBE). The precipitate was washed 2 times in MTBE, dissolved in a solvent (0.1% trifluoroacetic acid in 30%Acetonitrile/70%water) followed by freeze drying. Peptides were characterized by Ultra Performance Liquid Chromatography (UPLC) and Matrix Assisted Laser Desorption/Ionization Mass Spectrometry (MALDI-MS).

All peptides were dissolved initially in 100% DMSO at a concentration of 40 mM, prior to dilution at the appropriate concentration to create protein-specific peptide pools in RPMI-1640 medium.

Peptide pools of 15mer sequences (overlapping by 11 amino acids) covering the full length of wildtype spike, nucleocapsid, membrane, envelope and ORF3A were obtained from a commercial source (JPT peptide technologies). Overlapping Delta spike peptide pools were also obtained from JPT. For Omicron spike, nucleocapsid, membrane and envelope peptide paraformaldehyde, prior to flow cytometric analysis on a BD LSR II (BD Biosciences). A positive response was defined as one with a percentage of CD3 + CD8 + or CD3 + CD4 + CFSE low cells at least 1.5x greater than the highest of two negative-control wells and greater than 0.2% CD8 + or CD4 + CFSE low cells in magnitude following background subtraction. For graphical analyses, responses are plotted at a value of 0.1% CD8 + or CD4 + CFSE low cells.

Predicted binding affinities for all 8-11mer peptides in wildtype spike (N = 5058) and Omicron spike (N = 5050) to 150 HLA-A, -B, and -C alleles were calculated using NetMHCpan4.1 (https://services.healthtech.dtu.dk/service.php?NetMHCpan-4.1). Strong binders were those with an EL-Rank score <0.5, while weak binders had scores >0.5 and <2.0 and nonbinders had scores >2.0, with thresholds set as defined by NetMHC.

Locus-specific PCR primers were used to amplify polymorphic exons of HLA-A, HLA-B, HLA-C genes with the Fluidigm Access Array (Fluidigm). PCR amplicons were pooled and sequenced on an Illumina MiSeq platform (Illumina). HLA alleles and genotypes were called using the Omixon HLA Explore (beta version) software (Omixon). Ambiguous calls were resolved by Sanger sequencing.

Neutralization data is from our recent study in a subset of individuals described here and previously reported (Garcia-Beltran et al., 2021b) . In brief, pseudovirus neutralization titer 50 (pNT50) was calculated by taking the inverse of the serum concentration that achieved 50% neutralization of SARS-CoV-2 pseudotyped lentivirus particles entry into ACE2 expressing 293T cells (a gift from Michael Farzan). We introduced mutations corresponding to the SARS-CoV-2 variants of concern by site directed mutagenesis and confirmed clones by sequencing.

The primary statistical analysis shown in Table S3 and S5 was a multivariate regression modelling T-cell response (log10 CFU/10 6 PBMC) as the response variable, and age, sex, peptide pool, prior infection, vaccine type, duration from vaccination as covariates. To compare proportions of individuals we used a fishers-exact test. Analyses were performed in R and figures rendered in GraphPad Prism. A p-value of < 0.05 was considered significant. 

Advances in Fmoc solid-phase peptide synthesis

2-Chlorotrityl chloride resin: Studies on anchoring of Fmoc-amino acids and peptide cleavage

Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity

mRNA-based COVID-19 vaccine boosters induce neutralizing immunity against SARS-CoV-2 Omicron variant

COVID-19-neutralizing antibodies predict disease severity and survival

SARS-CoV-2 variants of concern partially escape humoral but not T cell responses in COVID-19 convalescent donors and vaccine recipients

Induction of multifunctional human immunodeficiency virus type 1 (HIV-1)-specific T cells capable of proliferation in healthy subjects by using a prime-boost regimen of DNA-and modified vaccinia virus Ankaravectored vaccines expressing HIV-1 Gag coupled to CD8+ T-cell epitopes

An antibody-escape calculator for mutations to the SARS-CoV-2 receptor-binding domain

Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals

The Omicron variant is highly resistant against antibody-mediated neutralization -implications for control of the COVID-19 pandemic

SARS-CoV-2 Omicron variant escapes neutralization by vaccinated and convalescent sera and therapeutic monoclonal antibodies

Comparison of the ELISPOT and cytokine flow cytometry assays for the enumeration of antigen-specific T cells

Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19

Correlates of protection against SARS-CoV-2 in rhesus macaques

Highly conserved, nonhuman-like, and cross-reactive SARS-CoV-2 T cell epitopes for COVID-19 vaccine design and validation

HIV-specific CD8+

T cell proliferation is coupled to perforin expression and is maintained in nonprogressors

Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control

Comparative immunogenicity and effectiveness of mRNA-1273, BNT162b2 and Ad26.COV2.S COVID-19 vaccines

Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses

High-dimensional immunomonitoring models of HIV-1-specific CD8 T-cell responses accurately identify subjects achieving spontaneous viral control

Rapid induction of antigenspecific CD4+ T cells is associated with coordinated humoral and cellular immunity to SARS-CoV-2 mRNA vaccination

Broad and strong memory CD4+ and CD8+ T cells induced by SARS-CoV-2 in UK convalescent individuals following COVID-19

NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and integration of MS MHC eluted ligand data

Antigen-Specific Adaptive Immunity to SARS-CoV-2 in Acute COVID-19 and Associations with Age and Disease Severity

SARS-CoV-2 genome-wide T cell epitope mapping reveals immunodominance and substantial CD8+ T cell activation in COVID-19 patients

Robust T cell immunity in convalescent individuals with asymptomatic or mild COVID-19. Cell

Early induction of functional SARS-CoV-2-specific T cells associates with rapid viral clearance and mild disease in COVID-19 patients

The use of DODT as a non-malodorous scavenger in Fmoc-based peptide synthesis

An infectious SARS-CoV

1.1.529 Omicron virus escapes neutralization by several therapeutic monoclonal antibodies

Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa

We thank Shiv Pillai, MD PhD for excellent advice on this manuscript. We thank Anand Dighe, MD, Andrea Nixon, BS, and the MGH Core Laboratory for assistance with clinical SARS-CoV-2 serology testing. This work was supported by the Peter and Ann Lambertus Family Foundation. This study was supported by NIH grants P01 DK011794-51A1 (A.K.),

 T-cell responses to Omicron are preserved in most infected and vaccinated individuals  T-cell reactivity to Omicron spike is reduced by >50% in ~20% of individuals  Most Omicron epitopes have conserved sequence and retain binding to HLA-I  T-cell reactivity to Omicron is enhanced shortly after booster vaccination

T cells from most SARS-CoV-2 infected and/or vaccinated individuals have preserved reactivity to the Omicron variant and reactivity is enhanced by booster vaccination. However, approximately 20% of individuals have reduced T-cell recognition of the Omicron spike, potentially due to escape of HLA class I-restricted epitopes.